Multicentric Castleman’s disease with voltage-gated potassium channel antibody-positive limbic encephalitis: a case report by Vikram R Rao et al.
Rao et al. BMC Neurology  (2015) 15:4 
DOI 10.1186/s12883-015-0266-8CASE REPORT Open AccessMulticentric Castleman’s disease with voltage-gated
potassium channel antibody-positive limbic
encephalitis: a case report
Vikram R Rao1*, Leland E Lim2,3, Dean Fong4, Nina I Garga5 and Karen L Parko5Abstract
Background: Castleman’s disease is a rare lymphoproliferative disorder which occurs in localized and multicentric
forms and can mimic lymphoma. Despite its well-known association with certain autoimmune diseases, including
paraneoplastic pemphigus and myasthenia gravis, Castleman’s disease has not previously been associated with
limbic encephalitis.
Case presentation: We report the case of a 47-year old Caucasian man who presented with subacute onset of
constitutional symptoms, diffuse lymphadenopathy, and stereotyped spells involving olfactory aura, nausea,
disorientation, and unresponsiveness. He was found to have focal dyscognitive seizures of temporal lobe origin,
cerebrospinal fluid with lymphocytic pleocytosis, hyponatremia, and serum positive for voltage-gated potassium
channel antibodies, consistent with limbic encephalitis. An extensive infectious workup was unrevealing, but
lymph node biopsy revealed multicentric Castleman’s disease. His symptoms improved with antiepileptic drugs
and immunotherapy.
Conclusion: This case highlights the clinical diversity of voltage-gated potassium channel autoimmunity and
expands the association of Castleman’s disease and autoimmune syndromes to include limbic encephalitis.
Clinicians should be aware that paraneoplastic disorders of the central nervous system can be related to
underlying hematologic disorders such as Castleman’s disease.
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Castleman’s disease (CD) is a rare lymphoproliferative dis-
order characterized by enlarged, hyperplastic lymph nodes
that can mimic lymphoma. First described in 1954 [1], CD
occurs in several histologic variants, including hyaline-
vascular, plasma cell, and mixed types. Two clinical pre-
sentations can be distinguished: a localized or unicentric
form, which is typically indolent and treated with local ex-
cision, and a systemic or multicentric form (MCD), which
usually involves the plasma cell variant and portends a
worse prognosis. MCD presents with diffuse lymphaden-
opathy, hepatosplenomegaly, fevers, night sweats, and fa-
tigue. The pathogenesis of MCD is thought to be driven* Correspondence: vikram.rao@ucsf.edu
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unless otherwise stated.by human herpesvirus 8 (HHV8), which latently infects B
cells in healthy individuals but can reactivate in the setting
of immune system compromise, such as human immuno-
deficiency virus (HIV) infection. Reactivated HHV8 pro-
motes production of interleukin-6 (IL-6), which stimulates
B cell proliferation and lymphoid hyperplasia, and treat-
ment of MCD can be directed at lowering levels of this
cytokine [2].
CD most commonly presents with lymphadenopathy
in the neck, chest, and/or abdomen. Central nervous
system (CNS) involvement is rare, but intracranial,
extra-axial lesions mimicking meningiomas have been
reported in CD and can present with seizures [3,4], pre-
sumably due to their direct impingement on cortex. CD
has been associated with several autoimmune diseases
[5], including paraneoplastic pemphigus, systemic lupus
erythematosus, rheumatoid arthritis, myasthenia gravis,is is an Open Access article distributed under the terms of the Creative
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clonal gammopathy, and skin changes (POEMS) syndrome,
but only a single report describes a paraneoplastic CNS
syndrome in the setting of CD [6]. Limbic encephalitis (LE),
a classic CNS autoimmune disorder, presents with cognitive
changes and focal seizures of mesial temporal lobe origin.
LE can occur with or without identifiable underlying
malignancy and can be seronegative or associated with
specific antibodies. Malignant hemopathies—including
leukemia [7] and, more commonly, lymphomas [8]—have
been associated with paraneoplastic LE, but, to our know-
ledge, CD has not.
Here we report the case of a patient who presented
with subacute onset of constitutional symptoms and sei-
zures and was found to have MCD, LE, and voltage-
gated potassium channel (VGKC) antibodies. This case
illustrates novel linkage of two rare clinical entities
through an antibody well-known to mediate paraneo-
plastic neurological syndromes.
Case presentation
A 47-year old Caucasian man with history of depression
and remote polysubstance abuse presented to his primary
care physician with two months of cough, dyspnea, and
asthenia. Chest radiography demonstrated patchy, diffuse
interstitial infiltrates. Chest computed tomography (CT)
disclosed diffuse lymphadenopathy, splenomegaly, and bi-
lateral bronchiectatic changes (Figure 1). Body positron
emission tomography (PET)/CT showed diffuse, hyper-
metabolic (mild-moderate 18 F-fluorodeoxyglucose (FDG)
uptake) lymphadenopathy without other evidence of ma-
lignancy. The initial differential diagnosis included atypical
respiratory infection, granulomatous disease, and lympho-
proliferative disorder. He underwent bronchoscopy with
bronchoalveolar lavage, with negative staining for acid-fast
bacilli, no malignant cells on cytology, and no growth in
bacterial and fungal cultures. Transbronchial lung biopsy
revealed non-specific chronic inflammation, and fine nee-
dle aspirate of a left neck lymph node was non-diagnostic.
A repeat bronchoscopic evaluation nine months later
was similarly unrevealing. Serum protein electrophoresis
showed no evidence of monoclonal gammopathy, and
angiotensin-converting enzyme levels were within normal
limits. Serum inflammatory markers were elevated (erythro-
cyte sedimentation rate 111 mm/hr, C-reactive protein
7.28 mg/dL), but an extensive biochemical evaluation for
infectious etiologies, including HIV, tuberculosis, coccidi-
oidomycosis, aspergillosis, cryptococcosis, blastomycosis,
and histoplasmosis, was negative. Due to an elevated
Strongyloides IgG antibody titer, he was treated with iver-
mectin but had no improvement in his symptoms.
While this workup was in progress, the patient de-
scribed progressive memory difficulty and recurrent, ste-
reotyped spells involving perception of an unpleasantodor followed by nausea and dizziness. The spells lasted
about one minute, occurred up to seven times per day,
and coincided with episodic confusion noticed by his
girlfriend. A routine electroencephalogram (EEG) was
normal, and the patient was treated empirically with le-
vetiracetam without benefit.
His neurological exam was notable for short-term mem-
ory impairment (1 out of 3 object recall after 5-minute
delay) and hyporeflexia with length-dependent sensory
loss in the lower extremities. Routine bloodwork revealed
hyponatremia, with serum sodium of 131 mmol/L. Lum-
bar puncture was performed, and cerebrospinal fluid
(CSF) analysis revealed glucose 55 mg/dL, total protein
33 mg/dL, and 12/mm3 white blood cells (88% lympho-
cytes, 11% monocytes) and 15/mm3 red blood cells. CSF
cytology was negative. Gadolinium-enhanced brain mag-
netic resonance imaging (MRI) at 3.0 Tesla was normal.
Video-EEG monitoring performed over two days captured
twelve electrographic seizures—most were subclinical but
some had associated dyscognitive features—with ictal on-
set over the left temporal region (Figure 2). Electrographic
features of the seizures, including early emergence of
rhythmic theta- and alpha-range frequencies, suggested
mesial temporal origin. Levetiracetam was substituted
with divalproex, which led to complete resolution of the
patient’s seizures based both on his report and on repeat
video-EEG monitoring one month later. His cognitive def-
icits also improved subjectively, though formal neuro-
psychological testing was not pursued.
The constellation of subacute encephalopathy, temporal
lobe seizures, and mild lymphocytic CSF pleocytosis raised
the possibility of autoimmune encephalitis. Serological
analysis revealed elevated voltage-gated potassium channel
(VGKC) antibodies (850 pmol/L; Athena Diagnostics,
reference range 31–88 pmol/L). Testing for N-methyl-
D-aspartate receptor and glutamic acid decarboxylase
antibodies was negative. VGKC antibodies can be associ-
ated with underlying neoplastic disease, and, to further
evaluate this possibility, excisional biopsy of a level V
lymph node in the right neck was performed.
Histologic sections revealed lymph nodes with variable
sized follicles, some with atrophic germinal centers
(Figure 3a). Germinal centers with penetrating vessels
were present, conferring a “lollipop” appearance (Figure 3b).
Mantle zone lymphocytes were arranged in concentric rings
(“onion-skinning”). The interfollicular areas and medulla
were expanded by large sheets of mature plasma cells.
No granulomas were seen. Immunohistochemistry dem-
onstrated the presence of polytypic plasma cells. Flow
cytometry provided no evidence for a clonal lymphocyte
population or aberrant antigen expression. IL-6 concen-
tration in undiluted serum was 7.12 pg/mL (reference
range 0.31-5.00 pg/mL) but the level was 174.08 pg/mL
when tested in serial dilutions, suggesting prozone
Figure 1 Lymphadenopathy on chest CT. Chest CT demonstrating enlarged lymph nodes (arrows) involving the right axillary (a), paratracheal
(b), subcarinal (c), and cardiophrenic (d) regions.
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ent with MCD, plasma cell variant. Of note, HHV8
staining of lymphoid tissue and serum HHV8 immuno-
fluorescence assay were both negative. Repeat HIV anti-
body testing was also negative.
The patient was treated with two four-week cycles of
weekly rituximab infusions followed by maintenance ri-
tuximab infusions every two months for a planned two-
year course. Antiepileptic drug therapy with divalproex
was continued with some dose adjustment required for
breakthrough seizures. Serum IL-6 levels were not moni-
tored to track response to therapy, but serial PET scans
have shown decreased size and FDG-avidity of diffuse
lymphadenopathy without complete resolution. A repeat
VGKC antibody titer six months after initiation of rituxi-
mab was lower but remained elevated at 656 pmol/L. At
last follow-up, the patient’s cough was persistent, now
being managed with prednisone, but the constitutional
symptoms that led to initial presentation had resolved.
Discussion
This case illustrates the typical features of MCD: onset
in middle age, non-specific constitutional symptoms
suggestive of inflammatory disease, diffuse lymphaden-
opathy and hepatosplenomegaly mimicking lymphoma,and, often, cough or dyspnea, which is more common in
HIV-positive patients and may relate to a non-infectious
pulmonary interstitial lymphocytic infiltrate. Mild sen-
sory polyneuropathy, as found in our patient, can occur
in 20% of patients with MCD [9]. Manifestations of
MCD are thus non-specific and diagnosis is made by
histopathology, which most commonly reveals the plasma
cell variant. Although HHV8 is central to the pathogenesis
of HIV-positive CD, its role in HIV-negative disease re-
mains controversial [9] because HHV8 is found in only
50% of these patients [10]. Our patient was found to be
HIV-negative and HHV8-negative, which may represent a
nosologically-distinct disease entity, termed idiopathic
MCD, whose pathogenesis is speculated to involve auto-
immune mechanisms [11]. Thus, this case raises the intri-
guing possibility that VGKC antibodies might be important
for the pathogenesis of certain forms of MCD.
Our patient also developed cardinal features of LE as-
sociated with VGKC antibodies, including subacute en-
cephalopathy, temporal lobe seizures, CSF lymphocytic
pleocytosis, and hyponatremia [12]. Brain MRI was nor-
mal, as is the case in up to 45% of patients with LE and
VGKC antibodies [13]. VGKC antibodies are thought to
be pathogenic in LE, but the antibodies are actually di-
rected against epitopes in the extracellular domains of
Figure 2 Ictal EEG. EEG during a seizure (red bar) arising from light sleep. Initially, there is emergence of theta/alpha range frequencies broadly
over the left temporal region, maximal at electrodes F7 and T3 (a). Left temporal waveforms become rhythmic (b) and evolve in frequency
and amplitude while acquiring sharpened elements (c) before return to interictal background (d). Clinically, the patient was observed to have
lip-smacking automatisms during this seizure.
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most common target in LE is the leucine-rich glioma-
inactivated 1 (LGI-1) protein [12]. Although we did not
test specifically for this immunoreactivity, our patient
did not demonstrate the faciobrachial dystonic seizure
semiology that often precedes onset of LE in LGI-1
antibody-positive patients [14].Figure 3 Lymph node biopsy pathology. 10x (a) and 20x (b) images of
microscope with Olympus SC100 camera and Olympus analySIS getIT softw
arranged in concentric rings create an “onion-skinning” appearance. Note t
(b) Germinal center with penetrating vessels and a “lollipop” appearance.Previous reports have described patients with intracra-
nial CD lesions presenting with seizures [3,4], presum-
ably due to mass effect and irritation of adjacent cortex.
CD is also known to be associated with paraneoplastic
syndromes affecting the peripheral nervous system
(PNS), including myasthenia gravis and POEMS syn-
drome [5]. One reported case of cerebellar degenerationlymph node tissue sections were captured on an Olympus BX40
are. (a) Atrophic germinal centers with mantle zone lymphocytes
hat the interfollicular areas are expanded by sheets of plasma cells.
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syndrome, but no antibody was identified [6]. Only 30%
of patients with antibodies against VGKC have tumors,
but VGKC antibodies have been reported in association
with thymoma and lung cancer [15]. To our knowledge,
this is the first report of CD associated with either LE or
VGKC antibodies.
LE associated with VGKC antibodies is frequently re-
sponsive to immunotherapy, and reduction in antibody
titer correlates with clinical improvement [16]. Our
patient’s seizures were relatively easily controlled with
antiepileptic drug monotherapy, though we cannot
exclude the possibility that steroids used later for pul-
monary indications also contributed to seizure control.
Rituximab was initiated primarily for treatment of
MCD. That only modest decrease in VGKC antibody
titer was seen following treatment with rituximab, how-
ever, may indicate that paraneoplastic LE in the setting
of MCD is more treatment-resistant than other forms of
LE. Three-year disease-free survival in HIV-negative pa-
tients with plasma cell variant MCD is 45% [17], so our
patient’s prognosis remains guarded. Other treatment
options, including the anti-IL-6 monoclonal antibody,
siltuximab [2], are being considered.
The range of autoimmune disorders associated with CD
is broader than previously known, and VGKC antibodies
may play an important pathogenic role. In addition to
paraneoplastic syndromes affecting the PNS, clinicians
should be aware that CD can be associated with LE and
other CNS manifestations even in the absence of overt
intracranial disease.
Conclusions
Castleman’s disease can be associated with voltage-gated
potassium channel antibodies and paraneoplastic syn-
dromes involving the central nervous system. Although
rare, Castleman’s disease should be considered in pa-
tients presenting with features of limbic encephalitis and
evidence of an underlying lymphoproliferative disorder.
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